Ketorolac Doc Generici

Ketorolac Trometamol, the active ingredient in Ketorolac Doc Generici, is a non‑steroidal anti‑inflammatory drug presented as an oral tablet for systemic administration. It provides potent analgesic and anti‑inflammatory effects and is indicated for the short‑term treatment of moderate to severe pain, especially following surgery or in acute pain episodes.

GNH USA supplies Ketorolac Doc Generici as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU pharmaceutical regulations and is available for export to multiple regions.

Ketorolac Trometamol is an NSAID that reduces pain by inhibiting cyclooxygenase-mediated prostaglandin synthesis.

- Moderate to severe acute pain: provides rapid analgesia for pain requiring opioid‑level relief. - Postoperative pain: helps control pain after surgical procedures, facilitating early mobilization. - Musculoskeletal or renal colic pain: offers short‑term relief when other analgesics are insufficient.

Ketorolac Trometamol may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dyspepsia or abdominal discomfort. - Nausea or vomiting. - Headache. - Dizziness. - Transient increase in serum creatinine. - Mild elevation of blood pressure.

Serious or Rare Side Effects: - Gastrointestinal bleeding or ulcer perforation. - Severe renal impairment or acute kidney injury. - Anaphylactic or severe hypersensitivity reactions. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Cardiovascular thrombotic events such as myocardial infarction. - Severe hepatic dysfunction.

Before prescribing Ketorolac Doc Generici, clinicians should evaluate patient‑specific risk factors and monitor for adverse events. - Renal impairment: avoid or use with caution in patients with reduced kidney function. - Gastrointestinal risk: assess history of ulcers or bleeding before use. - Cardiovascular caution: monitor patients with hypertension or heart disease. - Pregnancy and lactation: contraindicated unless benefits outweigh risks; safety not established. - Concomitant anticoagulants: increase bleeding risk; evaluate necessity. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Ketorolac may interact with several drug classes, requiring careful assessment.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): heightened bleeding risk. - Other NSAIDs or aspirin: additive gastrointestinal toxicity. - Selective serotonin reuptake inhibitors (SSRIs): increased bleeding potential. - Lithium: reduced renal clearance leading to toxicity. - Methotrexate: impaired elimination, risk of toxicity.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may reduce renal function. - Diuretics: potential for renal impairment. - Corticosteroids: enhanced ulcer risk. - Alcohol: may increase gastric irritation. - Beta‑blockers: may blunt antihypertensive effect.